Therapy and clinical trials in frontotemporal dementia: past, present, and future
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Frontotemporal dementia (FTD) is a common form of dementia with heterogeneous clinical presentations and distinct clinical syndromes. This article will review currently available therapies for FTD, its related disorders and their clinical evidence. It will also discuss recent advancements in FTD pathophysiology, treatment development, biomarker advancement and their relation to recently completed or currently ongoing clinical trials as well as future implications. image Frontotemporal dementia (FTD) is a type of dementia with distinct clinical syndromes. Current treatments involve off‐label use of medications for symptomatic management and cannot modify disease course. Advancements in FTD pathophysiology, genetics, and biomarkers have led to development of small molecules targeting the underlying pathology in hopes of achieving a disease‐modifying effect. This article will review current therapies for FTD, discuss advancements in FTD pathophysiology, therapy development, biomarker advancement, their relation to recent clinical trials and future implications. This article is part of the Frontotemporal Dementia special issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936 · cited 2×
“In 2011, a hexanucleotide repeat expansion in the 5 0 non-coding region of the C9ORF72 gene was found to be the cause of FTD and ALS in a strongly chromosome 9p linked family (Boxer et al. 2011; DeJesus-Hernandez et al. 2011; Renton et al. 2011).”
Self-citationA Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409 · cited 1×
“In 2011, a hexanucleotide repeat expansion in the 5 0 non-coding region of the C9ORF72 gene was found to be the cause of FTD and ALS in a strongly chromosome 9p linked family (Boxer et al. 2011; DeJesus-Hernandez et al. 2011; Renton et al. 2011).”
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Self-citationTau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy
Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949
RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention
Donnelly, C. J., Zhang, P.-W., Pham, J. T., Haeusler, A. R., Mistry, N. A., Vidensky, S., Daley, E. L., Poth, E. M., Hoover, B., Fines, D. M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.015 · Cited by 877
Tang, W., Lu, Y., Tian, Q.-Y., Zhang, Y., Guo, F.-J., Liu, G.-Y., Syed, N. M., Lai, Y., Lin, E. A., Kong, L., et al. (2011) · Science · doi:10.1126/science.1199214 · Cited by 761
Research works printed but not linked: 76
- 10.1007/s10072-014-1683-y · DOI
- 10.1021/bi00158a027 · DOI · Paper page
- 10.1016/j.neurobiolaging.2015.06.008 · DOI
- 10.1176/appi.neuropsych.12060158 · doi:10.1176/appi.neuropsych.12060158
- 10.1016/j.neuron.2013.02.004 · DOI · Paper page
- 10.1016/S0140-6736(15)00461-4 · DOI · Paper page
- 10.1002/mds.10211 · DOI
- 10.1097/WAD.0b013e318197852f · DOI · Paper page
- 10.1136/jnnp.2009.204081 · DOI · Paper page
- 10.1016/j.jalz.2012.03.003 · DOI · Paper page
- Brunden K. R., 2013, Microtubule‐stabilizing agents as potential therapeutics for neurodegenerative disease, Bioorg. Med. Chem., 5, 5040
- 10.1111/j.1750-3639.1999.tb00550.x · DOI · Paper page
- 10.1523/JNEUROSCI.5757-10.2011 · DOI · Paper page
- 10.3233/JAD-132477 · DOI · Paper page
- 10.1074/jbc.M110.193433 · DOI · Paper page
- 10.1074/jbc.M111.229633 · DOI · Paper page
- 10.1016/j.jagp.2013.01.060 · DOI · Paper page
- 10.1177/153331750201700504 · DOI · Paper page
- 10.1073/pnas.1301175110 · DOI · Paper page
- 10.1093/brain/awu213 · DOI · Paper page
- 10.1097/WNN.0b013e31816bdf73 · DOI · Paper page
- 10.1097/00004714-200006000-00018 · DOI · Paper page
- Dani M., 2015, Tau imaging in neurodegenerative diseases, Eur. J. Nucl. Med. Mol. Imaging, 16, 1139
- 10.1007/s00213-003-1686-5 · DOI · Paper page
- 10.1091/mbc.3.10.1141 · DOI · Paper page
- 10.1016/j.brainres.2012.02.030 · DOI · Paper page
- 10.1034/j.1600-0404.2001.103002123.x · DOI · Paper page
- 10.1097/00005072-199601000-00006 · DOI · Paper page
- 10.1080/15622970601016538 · DOI · Paper page
- 10.1093/brain/awn352 · DOI · Paper page
- 10.1212/WNL.0000000000001133 · DOI · Paper page
- 10.1002/ana.20365 · DOI · Paper page
- 10.1111/nan.12213 · DOI · Paper page
- 10.1212/01.wnl.0000325058.10218.fc · DOI · Paper page
- 10.1093/brain/awm032 · DOI · Paper page
- 10.1159/000439521 · DOI
- 10.1212/WNL.0b013e31821103e6 · DOI · Paper page
- 10.1097/JGP.0b013e31823033f3 · DOI
- 10.4088/JCP.v69n1219a · DOI · Paper page
- Kaye E. D., 2010, Frontotemporal dementia and pharmacologic interventions, J. Neuropsychiatry Clin. Neurosci., 22, 19, 10.1176/jnp.2010.22.1.19 · DOI
- 10.1111/j.1447-0594.2012.00956.x · DOI
- 10.1159/000114065 · doi:10.1159/000114065
- 10.1007/s00415-015-7657-z · DOI
- 10.1001/archneur.55.8.1099 · doi:10.1001/archneur.55.8.1099
- 10.1073/pnas.1318835110 · DOI · Paper page
- 10.1159/000077171 · DOI · Paper page
- 10.1002/ana.22424 · DOI · Paper page
- 10.1016/j.jalz.2009.04.1231 · DOI · Paper page
- 10.1212/WNL.57.3.467 · DOI · Paper page
- 10.1212/WNL.0000000000001642 · DOI · Paper page
- 10.1002/mds.20465 · DOI · Paper page
- 10.1097/WAD.0b013e31815bf774 · DOI · Paper page
- 10.1159/000067021 · DOI · Paper page
- 10.1177/153331750301800410 · DOI · Paper page
- 10.2165/00002512-200421140-00003 · DOI
- 10.1212/01.wnl.0000259519.78480.c3 · DOI · Paper page
- 10.1136/jnnp.2010.238899 · DOI
- 10.1002/gps.774 · DOI · Paper page
- 10.1097/JCP.0b013e31823f91b9 · DOI
- 10.1159/000051219 · DOI · Paper page
- 10.1136/jnnp.2009.173260 · DOI
- 10.1097/01.jcp.0000426190.64916.3b · DOI
- 10.1212/01.wnl.0000172911.39167.b6 · DOI · Paper page
- 10.1212/01.WNL.0000158425.46019.5C · DOI · Paper page
- 10.1186/alzrt149 · DOI
- 10.1111/j.1479-8301.2012.00429.x · DOI
- 10.1155/2013/547853 · DOI
- 10.1002/ana.21621 · DOI · Paper page
- 10.1097/WAD.0b013e318047df5d · DOI · Paper page
- 10.4088/JCP.v58n0506 · DOI · Paper page
- 10.1016/S1474-4422(08)70194-7 · DOI · Paper page
- 10.1001/jama.291.3.317 · DOI · Paper page
- 10.3233/JAD-2010-101632 · DOI · Paper page
- 10.1016/j.parkreldis.2011.10.013 · DOI · Paper page
- Yang Y., 2001, Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method, Acta Neuropathol., 101, 256, 10.1007/s004010000293 · DOI
- 10.1002/ana.10222 · DOI · Paper page
Cited by
Olney, N. T., Spina, S., & Miller, B. L. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.008 · Cited by 419
Tsoy, E., Kiekhofer, R. E., Guterman, E. L., Tee, B. L., Windon, C. C., Dorsman, K. A., Lanata, S. C., Rabinovici, G. D., Miller, B. L., Kind, A. J. H., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0399 · Cited by 182
18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
Tsai, R. M., Bejanin, A., Lesman-Segev, O., LaJoie, R., Visani, A., Bourakova, V., O’Neil, J. P., Janabi, M., Baker, S., Lee, S. E., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0470-7 · Cited by 164
Self-citationTemporal order of clinical and biomarker changes in familial frontotemporal dementia
Staffaroni, A. M., Quintana, M., Wendelberger, B., Heuer, H. W., Russell, L. L., Cobigo, Y., Wolf, A., Goh, S.-Y. M., Petrucelli, L., Gendron, T. F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01942-9 · Cited by 140
Self-citationProgranulin: a new avenue towards the understanding and treatment of neurodegenerative disease
Chitramuthu, B. P., Bennett, H. P. J., & Bateman, A. (2017) · Brain · doi:10.1093/brain/awx198 · Cited by 138
“Of several recent or ongoing trials for potential FTD disease-modifying drugs listed in ClinicalTrails.gov (Tsai and Boxer, 2016) only two are targeted towards increasing brain progranulin levels or secretion, namely a phase 2 trial with the histone deacetylase (HDAC) inhibitor FRM-0334…”
BackgroundInfluential
Metadata
- Authors
- Tsai, R. M., & Boxer, A. L.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-06-15
- Volume
- 138
- Issue
- S1
- Pages
- 211-221
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2443339653
- Cited by
- 143
- References
- 43
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- National Institutes of Health (U54NS092089, R01AG038791)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapy and clinical trials in frontotemporal dementia: past, present, and future. https://app.cochat.ai/papers/10.1111/jnc.13640
- The paper
- Tsai, R. M., & Boxer, A. L. (2016). Therapy and clinical trials in frontotemporal dementia: past, present, and future. Journal of Neurochemistry. https://doi.org/10.1111/jnc.13640
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.